GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD. The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse FSHD
GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD
Year-End Challenge to Fund the Treatment for FSHD!
Year-End Challenge to Fund the Treatment for FSHD! A group of long-time supporters have come forward to challenge the Society’s members and friends to make gifts to Fund the Treatment… Read More »
Canadian Foundation Launched!
Canadian Foundation Launched! Great news for Canadians who wish to support FSHD research! Canadians can now donate funds directly towards FSHD research — and receive a tax deduction. The FSHD… Read More »
Exciting news to report!
Exciting news to report! A watershed paper was published online in Nature Genetics identifying the mutation in a gene causing the non-chromosome-4-linked FSHD disease called FSHD1B or FSHD2
Progress in FSHD Muscular Dystrophy Research Hailed at International Meeting
San Francisco, CA / November 08, 2012 Just two decades ago, the scientific world largely ignored a mysterious disease that causes muscles to weaken throughout the body. Called fascioscapulohumeral muscular… Read More »